ICTIOSIS - AEDV

DERMATITIS ATÓPICA Y CALIDAD DE VIDA
• Gran afectación calidad de vida pacientes y sus
familias (66,4% afectación moderada) Pediatric
Dermatology 2010; 27 (6): 618-623)
• DA con alteración sueño riesgo de desarrollar
problemas emocionales y de conducta a los 10
años (hiperactividad/inatención)
• Círculo vicioso estrés psicológico y síntomas DA
(prurito). Acta Derm Venereol 2010; 90:582-588
DERMATITIS ATÓPICA:
¿Justificación dietas restrictivas?
PRO: Alergólogos CONTRA: Dermatólogos
• Los alimentos como
desencadenante y exacerbación
brotes
• FALSOS POSITIVOS: 1/3 de los
tests de alimentos son positivos
en la urticaria aguda, urticaria
de contacto, angioedema y rash
morbiliforme transitorio
• Sensibilización: MARCHA
ATÓPICA. Los antígenos
estimulan mucho más por la piel
que por las mucosas
• No justificado Prick-tests
• Quitar la comida no mejora.
DERMATITIS ATÓPICA:
¿Influencia tipo de dieta?
DERMATITIS ATÓPICA SEVERIDAD
• SCORAD Y EASI
• PO-SCORAD Y SA-EASI
© 2009 S. Karger AG, Basel
1018–8665/09/2183–0246$26.00/0
Fax +41 61 306 12 34
E-Mail karger@karger.ch Accessible online at:
www.karger.com
www.karger.com/drm
Clinical and Laboratory Studies
Dermatology 2009;218:246–251
DOI: 10.1159/000193997
Patient-Oriented SCORAD: A Self-
Assessment Score in Atopic Dermatitis
A Preliminary Feasibility Study
M. Vourc’h-Jourdain a S. Barbarot a A. Taieb b T. Diepgen c M. Ambonati d
V. Durosier d V. Sibaud d J.F. Stalder a
a Clinique Dermatologique, CHU Hôtel-Dieu, Nantes , et b Service de Dermatologie, CHU Bordeaux, Bordeaux , France;
c Department of Social Medicine, Occupational and Environmental Dermatology, University of Heidelberg,
Heidelberg , Germany; d Pierre Fabre Laboratoire, Fondation dermatite atopique, Boulogne, France
Key Words
Atopic dermatitis Self-assessment score Scoring Atopic
Dermatitis index, patient-oriented
Received: August 15, 2008
Accepted: October 22, 2008
Published online: January 16, 2009
the PO-SCORAD. Conclusion: This study shows that self-as-
sessment is feasible in AD, and that there is a correlation between
the physician and the patient scores. This study was
the first step in validating the PO-SCORAD.
Copyright © 2009 S. Karger AG, Basel
Abstract
Background: The SCORing Atopic Dermatitis (SCORAD) index
is used worldwide to assess the severity of atopic ecze- Introduction
ma. Patient involvement in the treatment process is of major
current interest. There are very few validated patient self- Atopic dermatitis (AD) affects between 5 and 20% of
assessment tools for atopic dermatitis (AD). Objective: To children under 11 years old [1, 2] and has significant im-
develop a self-assessment score for AD patients, the patientplications in terms of patient quality of life and health
oriented SCORAD (PO-SCORAD) based on the SCORAD in- economically [3–5] . Although treatments aim to resolve
dex, and to assess its acceptability in a pilot study. Methods: patients’ symptoms, more attention is being paid (in both
A multicenter working group decided on the initial form of daily practice and clinical trials) to assessment based on
the PO-SCORAD. A prospective, single-center pilot study objective clinical signs [6, 7] . The principal tools used in
was then carried out to assess its acceptability and validity. AD are: SCORAD (severity SCORing of Atopic Derma-
A SCORAD and a PO-SCORAD were applied at baseline and titis index [8] ), EASI score (Eczema Area and Severity
after 18 days; the acceptability of the tool was assessed by Index [9] ) and Six-Area Six-Sign Atopic Dermatitis sever-
questionnaire, its validity by comparing SCORAD and PO- ity score [10] which all combine several clinical criteria
SCORAD on both visits. Results: The study involved 15 chil- with a varying, but always lower, weight for subjective
dren and 18 adults. 80% of the respondents found the ques- symptoms.
tions clear and the form easy to fill in; 96% spent less than 10 Patient involvement in the treatment process is of
min on it. A correlation was found between the SCORAD and topical interest and is widely recommended by public
M. Vourc’h-Jourdain
Clinique Dermatologique, CHU Hôtel-Dieu
Place Alexis-Ricordeau
FR–44000 Nantes (France)
Tel. +33 240 083 116, Fax +33 240 083 117, E-Mail mvourch@yahoo.fr
DERMATITIS ATÓPICA:
¿Justificación dietas restrictivas?
DERMATITIS ATÓPICA:
¿Papel simbióticos?
• Niños DA